Stereotaxis STXS Q1 2026 Earnings EPS Miss Reflects Ongoing Investment in Robotic Cardiology Platform RDY Q1 2026 Earnings Significant EPS Miss Amid Challenging Quarter Ovid Therapeutics Q1 2026 Earnings NarrowerThanExpected Loss Supports Biotechs Cash Discipline FWONK Q4 2025 Earnings Slight EPS Miss Amidst Steady Formula One Performance DK Q1 2026 Earnings Narrow Profit Beats Deeply Negative Estimates PAPL Q3 2025 Earnings Narrowed Loss Beats Estimates by 51